¹⁸⁸Re-HEDP i.v. has already entered its clinical phase II trial. The Company intends to start further clinical trials with ¹⁸⁸Re-labelled monoclonal antibodies / peptides for therapeutics / diagnostics soon after ¹⁸⁸Re-HEDP has obtained its NDA from the NMPA.